Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2...
Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer
About this item
Full title
Author / Creator
Publisher
Boston: Boston : Springer US
Journal title
Language
English
Formats
Publication information
Publisher
Boston: Boston : Springer US
Subjects
More information
Scope and Contents
Contents
This multicenter, randomized, open-label phase III trial (planned enrollment: 700 patients) was conducted to test the hypothesis that single-agent sunitinib improves progression-free survival (PFS) compared with capecitabine as treatment for advanced breast cancer (ABC). Patients with HER2-negative ABC that recurred after anthracycline and taxane t...
Alternative Titles
Full title
Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2855860
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2855860
Other Identifiers
ISSN
0167-6806
E-ISSN
1573-7217
DOI
10.1007/s10549-010-0788-0
